For the first time, a GLP-1 for weight loss comes as a daily pill instead of a shot. The Wegovy pill's January debut removes the needle for many patients — and, by Novo Nordisk's account, became the strongest GLP-1 launch the U.S. has seen.
On January 5, 2026, Novo Nordisk launched the Wegovy pill — oral semaglutide 25 mg — in the United States, making it the first oral GLP-1 receptor agonist approved for chronic weight management. Until now, GLP-1 weight medications were available only as injections.
GLP-1 receptor agonists reshaped the weight-management landscape as injectables. The January 2026 U.S. launch of the Wegovy pill marks the category's first once-daily oral option for weight loss, removing the needle for patients who preferred to avoid injections.
The approval was supported by the OASIS clinical trial program. In OASIS 4 — a 64-week study in adults with obesity or overweight with at least one weight-related condition — once-daily oral semaglutide 25 mg produced a mean weight loss of about 13.6%, alongside lifestyle counseling. The product was also cleared to help reduce the risk of major adverse cardiovascular events in eligible patients, reflecting a broader shift toward viewing these medicines as cardiometabolic, not purely cosmetic, treatments.
Uptake was immediate. Novo Nordisk reported that the Wegovy pill launched on January 5 and that more than one million Americans began using it within roughly the first four months, with weekly prescriptions exceeding 200,000 by mid-April — which the company characterized as the strongest-ever GLP-1 volume launch in the U.S.
For the "convergent" consumer — someone weighing weight management alongside aesthetic goals — an oral option lowers a practical barrier to starting treatment. It also intensifies an already crowded market and raises familiar questions about access, insurance coverage, and the difference between FDA-approved branded products and compounded alternatives (covered separately in this edition). As with any prescription medicine, suitability is an individual clinical decision made with a licensed prescriber.